MXC.AX - MGC Pharmaceuticals Limited

ASX - ASX Delayed price. Currency in AUD

MGC Pharmaceuticals Limited

1202 Hay Street
West Perth, WA 6005
Australia
61 8 6382 3390
http://www.mgcpharma.com.au

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Brett Anthony MitchellExec. Chairman289.76kN/A1973
Mr. Roby Reuven ZomerCo-Founder, CEO, MD & Exec. Director406.41kN/AN/A
Mr. Nativ SegevCo-Founder, Head of Bus. Strategy & Exec. Director393.54kN/AN/A
Ms. Rachel Jelleff KerrCompany Sec.N/AN/AN/A
Hugh WintersChief Exec. Officer of MGC DermaN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and supplies medicinal cannabis products in Australia, Slovenia, and other European countries. It is developing phytocannabinoid, an active pharmaceutical ingredients (API) for medicinal cannabis products. The company offers MGC MX201 for nausea, vomiting, pain related to chemotherapy treatment, and Tourette syndrome disorder; and MGC MX21 for acquired immunodeficiency syndrome (AIDS), weight loss CAC, and the enhancement of appetite or relief from gastrointestinal vomiting and symptoms, and Parkinson's disease. It also offers MGC MX11 for neuropathy, multiple sclerosis, and Tourette syndrome; and MGC MX120 for epilepsy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and post-traumatic stress disorder. In addition, the company provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; CannEpil and CannEKids for refractory epilepsy; and TopiCann for anti-inflammatory topical treatment. Further, it offers MGC CBD for anti-inflammatory, antioxidant, neuroprotector, anxiolytic, analgesic, antidepressant, anti-psychotic, and anti-tumoral agent; and MGC THC for nausea and vomiting associated with cancer medicines, as well as enhance the appetite of people with AIDS. Additionally, the company offers nutraceuticals, including CBD cosmetics and hempenhanced products for retail customers online. MGC Pharmaceuticals Limited has a collaboration with Epilepsy Action Australia to create an online platform for providing information and education on medicinal cannabis and epilepsy; and partnership with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to form a medical research hub for medicinal cannabis technologies. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Corporate governance

MGC Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.